Clinical Trial Update: Alemtuzumab to Treat Sporadic Inclusion Body Myositis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating alemtuzumab for inclusion body myositis has completed; the snippet does not provide trial results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inclusion Body Myositis

Drugs mentioned

• Alemtuzumab (Alemtuzumab)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Myositis, Inclusion Body | Phase 2 | Status: COMPLETED